文献速递肝病

丙型肝炎治疗的持续病毒学应答降低2型糖尿病相关并发症发生率

Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes.
PubMed 文献 · Aliment Pharmacol Ther · 2019-01-16

在慢性肝炎队列研究(CHeCS)的四个美国卫生系统中,1395例接受降糖药物治疗的丙型肝炎合并2型糖尿病患者中,723例(52%)接受干扰素或直接抗病毒药物治疗,539例(75%)获得持续病毒学应答(SVR)。经倾向评分调整后,与未治疗患者相比,获得SVR者急性冠脉综合征、终末期肾病、卒中和视网膜病变风险显著降低。

要点

  • 合并2型糖尿病的丙型肝炎患者中,获得SVR者急性冠脉综合征风险显著低于未治疗者(sHR=0.36)。
  • 获得SVR者终末期肾病风险显著低于未治疗者(sHR=0.46),卒中风险显著低于未治疗者(sHR=0.34)。
  • 获得SVR者视网膜病变风险显著低于未治疗者(sHR=0.24),亚组和敏感性分析结果一致。

核心结论

  • 在2型糖尿病患者中,成功的丙型肝炎治疗可显著降低急性冠脉综合征、终末期肾病、缺血性卒中和视网膜病变的发生率,无论是否存在肝硬化。
  • 研究结果支持在2型糖尿病患者中进行丙型肝炎抗病毒治疗以降低这些肝外结局的风险。

研究设计与样本

  • 研究纳入慢性肝炎队列研究(CHeCS)四个美国卫生系统中具有2型糖尿病诊断代码且正在使用降糖药物的丙型肝炎病毒感染患者。
  • 共纳入1395例丙型肝炎病毒感染合并2型糖尿病患者,其中723例(52%)接受干扰素为基础或直接抗病毒药物(DAA)治疗,539例(占治疗者的75%)获得持续病毒学应答(SVR)。
  • 随访至出现目标结局、死亡或最后一次卫生系统就诊,采用竞争风险分析(Fine-Gray子分布风险比[sHR])评估治疗对结局的影响,以死亡为竞争事件。

主要发现

  • 经倾向评分调整后,与未治疗患者相比,获得SVR的患者急性冠脉综合征风险显著降低(sHR=0.36;P<0.001)。
  • 获得SVR的患者终末期肾病风险显著降低(sHR=0.46;P<0.001),卒中风险显著降低(sHR=0.34;P<0.001),视网膜病变风险显著降低(sHR=0.24;P<0.001)。
  • 在DAA治疗亚组、干扰素治疗亚组、肝硬化患者分析以及考虑病因特异性风险、排除治疗期间视网膜病变患者和以治疗状态为时间变化协变量的敏感性分析中,结果一致。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The role of hepatitis C (HCV) eradication on the long-term complications of type 2 diabetes mellitus remains incompletely studied. AIM: To investigate whether antiviral treatment impacted risk of acute coronary syndrome, end-stage renal disease, ischaemic stroke, and retinopathy among diabetic patients from the four US health systems comprising the Chronic Hepatitis Cohort Study (CHeCS). METHODS: We included CHeCS HCV patients with diagnosis codes for type 2 diabetes who were on antidiabetic medications. Patients were followed until an outcome of interest, death, or last health system encounter. The effect of treatment on outcomes was estimated using the competing risk analysis (Fine-Gray subdistribution hazard ratio [sHR]), with death as a competing event. RESULTS: Among 1395 HCV-infected patients with type 2 diabetes, 723 (52%) were treated with either interferon-based or direct-acting antivirals (DAAs); 539 (75% of treated) achieved sustained virological response (SVR). After propensity score adjustment to address treatment selection bias, patients with SVR demonstrated significantly decreased risk of acute coronary syndrome (sHR = 0.36; P < 0.001), end-stage renal disease (sHR = 0.46; P < 0.001), stroke (sHR = 0.34; P < 0.001), and retinopathy (sHR = 0.24; P < 0.001) compared to untreated patients. Results were consistent in subgroup analyses of DAA-treated patients and interferon-treated patients, an analysis of cirrhotic patients, as well as in sensitivity analyses considering cause-specific hazards, exclusion of patients with on-treatment retinopathy, and treatment status as a time-varying covariate. CONCLUSION: Successful HCV treatment among patients with type 2 diabetes significantly reduces incidence of acute coronary syndrome, end-stage renal disease, ischaemic stroke, and retinopathy, regardless of cirrhosis. Our findings support the importance of HCV antiviral therapy among patients with type 2 diabetes to reduce the risk of these extrahepatic outcomes.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Li J, Gordon SC, Rupp LB, et al. Sustained virological response to hepatitis C treatment decreases the incidence of complications associated with type 2 diabetes. Aliment Pharmacol Ther. 2019. PMID: 30650468. doi:10.1111/apt.15102

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。